Home › Funds › Almitas Capital LLC › LYEL

Almitas Capital LLC position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

Almitas Capital LLC reported holding 581,407 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$8.2M, representing 1.96% of its reported portfolio and ranking #10 among its reported holdings. Almitas Capital LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)581.41K sh
Reported value held$8.17M
Portfolio Weight1.96%
First reportedQ4 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Almitas Capital LLC's LYEL position evolved

Almitas Capital LLC first disclosed a stake in LYEL in Q4 2024 at 1,050,520 shares (US$672K). The position peaked in Q4 2025 at 577,807 shares, worth US$17.8M. Across 7 filings, Almitas Capital LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 581,407 shares valued at US$8.2M — an increase of 3,600 shares quarter over quarter.. Notable position changes include a 136% increase in Q1 2025 (shares fell 18% over the following quarter), a 77% trim in Q2 2025 (shares rose 84% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.05M $672.33K New
Q1 2025 2.48M $1.34M Add
Q2 2025 580.00K $5.13M Reduce
Q3 2025 577.81K $9.38M Hold
Q4 2025 577.81K $17.78M Hold
Q1 2026 577.81K $11.59M Hold
Q2 2026 581.41K $8.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has Almitas Capital LLC held LYEL?

Almitas Capital LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Almitas Capital LLC's current position in LYEL?

As of Q2 2026, Almitas Capital LLC holds 581.41K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $8.17M, representing 1.96% of its reported portfolio and ranking #10.

Has Almitas Capital LLC been buying or selling LYEL?

In the latest 13F filing (Q2 2026), Almitas Capital LLC increased its position in LYEL. The position peaked in Q4 2025 at 577.81K shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Orland Properties Ltd, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.